Opko Health, Inc.
4400 Biscayne Boulevard
239 articles with Opko Health, Inc.
Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims.
Rosen Law Firm Reminds OPKO Health, Inc. Investors of Important Deadline in First Filed Case by Firm - OPK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of OPKO Health, Inc. from September 26, 2013 through September 7, 2018, inclusive (the "Class Period") of the important November 13, 2018 lead plaintiff deadline in the first filed case commenced by the Rosen Firm. The lawsuit seeks to recover damages for OPKO investors under the federal securities laws.
OPK LOSS NOTICE ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against OPKO Health, Inc.; Important Deadline - OPK
Rosen Law Firm announces it has filed a class action lawsuit on behalf of purchasers of the securities of OPKO Health, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OPKO Health - OPK
Pomerantz LLP is investigating claims on behalf of investors of OPKO Health
OPKO Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against OPKO Health, Inc. - OPK
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of OPKO Health, Inc.
OPKO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In OPKO Health To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against OPKO Health, Inc.
OPKO is working expeditiously to respond to Nasdaq’s request for information, but it cannot currently estimate when trading will resume.
OPKO Health, Inc. provided the following comment on the lawsuit filed by the U.S. Securities and Exchange Commission earlier today.
OPKO Health’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the most recent quarter.
The Company has begun a search for his replacement and, in the interim, a committee of senior management will assume operational responsibilities.
The deal is aimed at identifying novel genes and pathways to help manage human genetic diseases.
OPKO Health Enrolls First Patient in Phase IIB Study of OPK88004 to Treat Benign Prostatic Hypertrophy
Enlarged prostate affects approximately 50 million men in the U.S.
OPKO’s senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time today.
OPKO Health Submits Premarket Approval Application with FDA for a Point-of-Care PSA Test with the Claros 1 Platform
The filing contains clinical data from the Company’s 864-patient Total PSA clinical study.
Here are four players that have the right combination of elements to post an earnings beat this quarter.
Opko Health’s BioReference And The Garage Announce National Strategic Affiliation To Enhance Value-Based Care
Opko Health’s GeneDx To Showcase Leadership In Genetic Testing At The National Society Of Genetic Counselors And The American Society of Human Genetics Annual Meetings
Sandra Cole Appointed Vice President And Chief Compliance Officer For Opko Health's BioReference Laboratories